Cyclic Lipodepsipeptides in Novel Antimicrobial Drug Discovery by Nina Bionda & Predrag Cudic
 
† This article belongs to the Special Issue Chemistry of Living Systems devoted to the intersection of chemistry with life. 
* Author to whom correspondence should be addressed. (E-mail: pcudic@tpims.org) 
CROATICA CHEMICA ACTA 
CCACAA, ISSN 0011-1643, e-ISSN 1334-417X 
Croat. Chem. Acta 84 (2) (2011) 315–329. 
CCA-3478 
Review 
Cyclic Lipodepsipeptides in Novel Antimicrobial Drug Discovery† 
Nina Bionda and Predrag Cudic* 
Torrey Pines Institute for Molecular Studies, 11350 SW Village Parkway, Port St. Lucie, FL 34987, USA 
RECEIVED DECEMBER 22, 2010; REVISED MARCH 11, 2011; ACCEPTED MARCH 17, 2011 
 
Abstract. Naturally occurring cyclic depsipeptides, microbial secondary metabolites that contain one or 
more ester bonds in addition to the amide bonds, have emerged as an important source of pharmacologi-
cally active compounds or promising lead structures for the development of novel synthetically derived 
drugs. In particular, their lipidated derivatives have shown the greatest therapeutic potential as antimi-
crobial agents. Some of those compounds are either already marketed (daptomycin 37) or in advanced 
stages of clinical development (ramoplanin 32) for the treatment of complicated infections caused by mul-
tidrug-resistant bacterial strains. As bacteria progressively become resistant to frontline antimicrobial 
agents, our capacity to effectively treat bacterial infections becomes severely hindered. Therefore, identi-
fying novel antibacterial targets and new antibacterial chemotherapeutics capable of treating infections 
from drug-resistant microorganisms is of vital importance.(doi: 10.5562/cca1819) 
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INTRODUCTION 
Historically natural products have served as important 
sources of pharmacologically active compounds or lead 
structures for the development of new drugs.1−3 Although 
natural product research efforts have recently lost popu-
larity in the industry,4 a large number (over 25 %) of 
new drugs approved between 1981 and 2006 are of natu-
ral origin.5−7 Among natural products, peptides are par-
ticularly interesting because of the key roles they play in 
biological processes. In 2004 more than 40 peptides 
were in the world market for clinical applications, and 
more than 400 were in advanced preclinical phases 
worldwide.8 Peptides’ potential for high efficacy and 
their minimal side effects combined with advances in 
solid-phase synthetic chemistry, purification technology 
and new strategies for peptide drug delivery made them 
widely considered as lead compounds in drug develop-
ment.9−11 At present, peptide-based therapeutics exist for 
a wide variety of human diseases, including osteoporosis 
(calcitonin), diabetes (insulin), infertility (gonadorelin), 
carcinoid tumors and acromegaly (octreotide), hypothy-
roidism (thyrotropin-releasing hormone [TRH]), and 
bacterial infections (vancomycin, daptomycin).12 
However, despite the great potential, there are still 
some limitations for peptides as drugs per se. Major 
disadvantages are short half-life, rapid metabolism, and 
poor oral bioavailability.13 Nevertheless, pharmacoki-
netic properties of peptides can be improved by various 
modifications.12 Peptidomimetic modifications or cycli-
zation of linear peptides are frequently used as an attrac-
tive method to provide more conformationally con-
strained and thus more stable and bioactive 
peptides.14−19 In addition, replacement of the amide 
groups that undergo proteolytic hydrolysis with ester 
groups may lead to longer-acting compounds not so 
prone to proteolysis.20−23 Considering all these modifi-
cations that can potentially improve peptide metabolic 
stability, naturally occurring cyclic depsipeptides that 
contain one or more ester bonds in addition to the amide 
bonds have emerged as promising lead compounds for 
drug discovery. Cyclic depsipeptides belong to a large 
and diverse family of nonribosomally synthesized pep-
tides that have a wide variety of important biological 
activities.24,25 The biosynthesis of these peptides 
proceeds nonribosomally and is catalyzed by complex 
multi-functional enzymes; termed non-ribosomal pep-
tide synthases (NRPSs). NRPSs have unique modular 
structure in which each module contains the requisite 
domains for the recognition and activation of a single 
amino acid, generating huge structural and functional 
diversity of nonribosomal peptides.26 It is very well 
documented that cyclic depsipeptides and their lipidated 
derivatives exhibit a broad spectrum of biological ac-
tivities including insecticidal, antiviral, antimicrobial, 
antitumor, tumorpromotive, anti-inflammatory, and 
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immunosuppressive actions. Perhaps, lipidated cyclic 
depsipeptides have shown the greatest therapeutic po-
tentials, particularly as antimicrobial agents. There are 
numerous literature reports describing their isolation, 
characterization, and antimicrobial activities. Here, we 
summarize all these efforts, and discuss the role and 
applications of cyclic lipodepsipeptides from a new 
antibiotic discovery perspective. 
 
KATANOSIN A AND LYSOBACTIN  
(KATANOSIN B) 
Katanosin A 1 and lysobactin 2 (also known as katano-
sin B) are lipophilic, cyclic depsipeptides isolated in 
1988 independently from two sources. Shionogi & Co., 
Japan, isolated the two natural products from a strain 
related to the genus Cytophaga, whereas the Squibb 
Institute, USA, isolated lysobactin from Lysobacter sp. 
SC 14067.27−30 These two natural products have a ma-
crocyclic core composed of nine amino acids connected 
via lactone bridge between L-threo--phenylserine (L-
tPhSer) and C-terminal L-Ser11. A hydrophobic D-Leu-
L-Leu side chain is attached to the N-terminus of L-
tPhSer3, Figure 1. Out of eleven amino acids, six are 
nonproteinogenic, including L-tPhSer, L-threo--
hydroxyaspartic acid (L-tHyAsp), L-hydroxyleucine (L-
HyLeu), L-allo-threonine (L-aThr) and two D-amino 
acids, D-Arg and D-Leu. The main structural difference 
between katanosins A 1 and lysobactin (katanosin B) 2 
lies in the amino acid residue at position 7, Figure 1. 
Katanosin A contains a Val residue, whereas lysobactin 
contains Ile residue.27−29,31,32 Several groups have re-
ported synthesis of lysobactin fragments,33−38 and an 
Fmoc solid-phase synthesis of katanosin A and lysobac-
tin analogs containing Asp10, Thr8, Leu4 instead of L-
tHyAsp10, L-aThr8, and L-HyLeu4 residues has been 
reported by Egner and Bradley.39 The first total solu-
tion-phase syntheses of lysobactin have been reported 
recently. In 2007 von Nussbaum et al. at Bayer AG 
reported a synthesis of lysobactin rationalized by its 
crystal structure.40 A key step in this synthesis, peptide’s 
macrocyclic core assembly, was achieved via conforma-
tion–directed cyclization in which H-bonding involving 
unprotected hydroxyl side chains of amino acids plays a 
crucial role. Consequently, no side chain hydroxyl 
group protections are required, simplifying somewhat 
lysobactin’s total synthesis. Shortly afterward, Van 
Nieuwenhze et al. reported peptide-chemistry based 
solution phase total synthesis of lysobactin.41 
Both natural products show quite potent in vitro 
activity against Gram-positive bacteria such as antibiot-
ic-resistant Staphylococcus aureus, Enterococcus fae-
cium, Streptococcus pyogenes, Streptococcus pneumo-
niae and Enterococcus faecalis. Reported antibacterial 
activity, as indicated by the minimum inhibitory con-
centrations (MIC), ranged from 0.1 to 0.8 g/mL.27,30 
Katanosin A and lysobactin exhibit promising in vivo 
activity as well, as demonstrated by their curative ef-
fects when administered subcutaneously to mice in-
fected with Gram-positive pathogens, Table 1.27 Modest 
to no activity against Gram-negative bacteria has been 
reported.30 The spectrum of antibacterial activity for 
lysobactin parallels that of vancomycin, although lyso-
bactin is four times more potent. It is, however, slightly 















































R=H Katanosin A 1
R=CH3 Lysobactin (Katanosin B) 2
Figure 1. Structures of katanosin A 1 and lysobactin (katano-
sin B) 2. 
Table 1. In vivo efficacy of katanosin A 1 and lysobactin 




ED50 mg/kg × 2 
Lysobactin 
(Katanosin B) 
ED50 mg/kg × 2 
 S. aureus Smith  1.20 0.67 
 S. aureus SR 2030  1.90 0.77 
 S. pyogenes C-203 2.86 1.55 
 S. faecalis SR 700 2.10 1.80 
(a) Compounds were administered subcutaneously at 1 and 5 h 
after infection. 
Table 2. In vivo toxicity of lysobactin (katanosin B) 2 and 
vancomycin30 
LD50 (mg/kg) 
 Antibiotic iv(a) ip(b) 
 Lysobactin (Katanosin B) 77 132 
 Vancomycin >400 >1000 
(a) iv = intravenously; (b) ip = intraperitoneally. 
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structure determination of lysobactin and structural 
requirements for its biological activity.31 Based on lyso-
bactin’s semisynthetic modifications, it was demonstrat-
ed that the macrocyclic lactone bridge and N-terminal 
D-Leu1 are crucial structural elements contributing to its 
antibacterial activity. Experiments performed by Bonner 
et al.30 have suggested that lysobactin is primarily a cell 
wall acting agent probably affecting a step prior to 
UDP-N-acetylglucosamine formation. According to 
recent data published by Maki et al.,42 lysobactin inhi-
bits the transglycosylation and transpeptidation steps of 
bacterial cell wall biosynthesis by an unidentified me-
chanism that differs from the D-Ala-D-Ala binding 
characteristic for vancomycin, a drug of choice for 
treatments of infections caused by resistant bacterial 
strains. It was shown that lysobactin inhibits nascent 
peptidoglycan biosynthesis much like vancomycin; but 
unlike vancomycin, it also inhibits lipid intermediate 
formation. Interestingly, the MIC of lysobactin against 
S. aureus SRM133 was not affected by addition of 
acetyl-Lys-D-Ala-D-Ala, while the MIC of vancomycin 
increased significantly.42 These data strongly suggest 
that the inhibition of bacterial cell wall biosynthesis is a 
result of binding to lipid intermediates, substrates of 
several successive enzymes, rather than a result of the 
direct effect on one enzyme. However, lysobactin’s 
mode of action is not yet precisely understood. 
 
PLUSBACINS 
Plusbacin family of antibiotics, Figure 2, were isolated 
in 1992 from Pseudomonas sp. strain PB-6250 by Shio-
nogi & Co., the same group that discovered 
katanosins.43 Plusbacins are eight-residue depsipeptides 
cyclized by a lactone bridge between the fatty acid hy-
droxyl group in position 3 and the C-terminal L-
tHyAsp8, Figure 2. Out of eight amino acids, only one is 
proteinogenic. The rest are D-amino acids and/or hy-
droxylated amino acids, including D- and L-tHyAsp 
acid and L-hydroxyproline (L-HyPro). Plusbacins were 
divided into two families, A and B. The family A  
 
(A1−A4) contains L-HyPro
3; whereas in family B 
(B1−B4), this residue is replaced with Pro
3. The struc-
tures of fatty acids differ within the families, Figure 2.44 
Plusbacins A1 3 and B1 7 have the same fatty acid, and it 
is assumed to be 3-hydroxy-tetradecanoic acid. Plusba-
cinsA2 4 and B2 8 have 3-hydroxy-isopentadecanoic 
acid, A3 5 and B3 9 have 3-hydroxy-isohexadecanoic 
acid, and A4 6 and B4 10 have 3-hydroxy-hexadecanoic 
acid. However, the stereochemistries of the fatty acids’ 
carbon atoms bearing hydroxyl groups were not re-
ported. All lipodepsipeptides showed remarkable anti-
microbial activity in vitro against several Gram-positive 
bacteria, including E. faecalis, vancomycin-resistant E. 
faecium (VRE) and methicillin-resistant S. aureus 
(MRSA), with MICs ranging from 0.05 to 6.3 g/mL. 
Among plusbacins, plusbacin A3 5 showed the most 
potent antibacterial activity.42,43 None of the plusbacins 
were active against the Gram-negative bacteria tested, 
including Escherichia coli and Klebsiella pneumoniae. 
Curative effects in mice infected with S. aureus and S. 
pyogenes were observed with plusbacins A2 4 and A3 5, 
demonstrating plusbacins’ in vivo potency.43 Experi-
ments described by Maki et al. indicated that the most 
potent plusbacin, A3 5, inhibits bacterial peptidoglycan 
biosynthesis in the same fashion as lysobactin (katano-
sin B).42 As in the case of lysobactin, the precise me-
chanism of action has yet to be determined. In 2007 
VanNieuwenhze et al. reported total synthesis of plus-
bacin A3 in solution.
45 Their synthetic approach was 
guided by the feasibility of the final macrolactamization 
step and by their hypothesis that the hydroxyproline 
residues may enforce a -turn type of conformation 
facilitating the desired conformation during the final 
cyclization step. Two plusbacins A3 were synthesized 
differing in the stereochemistry of the fatty acid carbon 
atom in position 3. Comparison of these two synthetic 
compounds with the natural product revealed the (R)-
configuration of the 3-hydroxyisopentanoic acid. De-
spite promising in vitro and in vivo antibacterial activi-
ties, there are no reports yet of clinical trials involving 
either lysobactin or plusbacin. 
 
 
Figure 2. Structures of plusbacins A1-A4 3-6 and B1-B4 7-10. 
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LI-F/FUSARICIDINS 
LI-Fs or fusaricidins are a family of cyclic lipodepsipep-
tide antifungal antibiotics isolated from Paenibacillus 
sp., Figure 3.46−48 Their common structural feature is the 
macrocyclic portion consisting of six amino acid resi-
dues, three of which, Thr1, D-aThr4, D-Ala6 are con-
served throughout the family, and a 15-guanidino-3-
hydroxypentadecanoic acid attached via amide bond to 
the N-terminal Thr1. LI-Fs/fusaricidins are cyclized by a 
lactone bridge between N-terminal Thr1 hydroxyl group 
and C-terminal D-Ala.6 In 1987 Kurusu and Ohba re-
ported isolation of LI-Fs from Paenibacillus polymyxa 
L-1129 strain.46,49 Although RP HPLC analysis of the 
antifungal antibiotics mixture isolated from the fermen-
tation broth showed the presence of at least ten com-
pounds, only five were isolated, which were subse-
quently named LI-F03, F04, F05, F07 and F08. It was 
also noticed that each isolated antifungal antibiotic was, 
in fact, a mixture of two homologous components that 
were not successfully separated at the time.46 In 2000 
Kuroda et al. reported sequences of all isolated mem-
bers of LI-F family 11-22.49 The (R)-configuration of 
fatty acid for LI-F04a 13 was determined just recently 
upon total synthesis of both fatty acid enantiomers and 
their comparison with the natural LI-F04a.50 However, it 
is not yet known whether this stereochemistry is con-
served within the family. All isolated antimicrobials 
showed high activity against a variety of fungi and 
Gram-positive bacteria, whereas no activity was ob-
served against Gram-negative bacteria.46 Approximately 
ten years after the discovery of the LI-F family of anti-
fungal antibiotics, Kajimura and Kaneda isolated a se-
ries of compounds named fusaricidins from the culture 
broth of P. polymyxa KT-8 strain.47,48 Fusaricidins A−D 
11−14, Figure 3, are analogous to the LI-F family of 
antimicrobial antibiotics. In fact, LI-F peptides were 
later determined to be mixtures containing previously 
structurally characterized and new fusaricidins.49,51 Out 
of four isolated fusaricidin antibiotics, fusaricidin A (LI-
F04a) 13,49 showed the most promising antimicrobial 
activity against a variety of fungi, including clinically 
important Candida albicans and Cryptococcus neofor-
mans. Fusaricidin A (LI-F04a) also exhibits potent ac-
tivity against Gram-positive bacteria such as S. aureus 
(MICs ranging from 0.78−3.12 g/mL for most of the 
tested strains). LI-Fs/fusaricidins did not, however, 
show activity against Gram-negative bacteria.47,48 Low 
acute toxicity in mice have been reported for LI-F03, 
LI-F04, LI-F05, LI-F07, and LI-F08 (LD50 150−200 
mg/kg).46 LI-Fs/fusaricidins’ mode of action is still 
unknown. Two solid-phase synthetic approaches toward 
the most active fusaricidin A (LI-F04a) 13 have been 
reported recently. Stawikowski and Cudic reported in 
2006 Fmoc solid-phase synthesis of a fusaricidin A (LI-
F04a) analog 23 containing 12-guanidino dodecanoic 
acid instead of naturally occurring 15-guanidino-3-
hydroxyhexadecanoic acid.52 One reported synthetic 
approach includes resin attachment of the first amino 
acid, D-Asp,5 via side chain, successful combination of 
four quasiorthogonal temporary protecting groups, 
stepwise Fmoc solid-phase synthesis of a linear precur-
sor peptide, lipid tail attachment followed by last amino 
acid coupling via ester bond and on-resin head-to-tail 
macrolactamization. This strategy allows the complete 
suppression of the undesired ON acyl shift, and an 
efficient automated solid-phase synthesis of cyclic lipo-
depsipeptides.52 Since the entire synthesis was accom-
plished on the solid support, this opens a possibility for 
combinatorial modification of fusaricidin A (LI-F04a) 
 
Figure 3. Structures of LI-F family of compounds 11-22 and synthetic analog 23. 
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natural products and their analogs. Total synthesis of 
this natural product was reported in 2010 by Cochrane 
et al. In this approach, a linear peptide sequence was 
assembled on a solid-support using Fmoc-chemistry, 
followed by peptide cleavage, in solution macrolactoni-
zation, and final attachment of 15-guanidino-3-
hydroxyhexadecanoic acid.50 Both enantiomers of this 
fatty acid were assembled by Yamaguchi-Hiaro alkyla-
tion of corresponding chiral epoxide precursors. By 
comparison of the optical rotations of both synthetic 
fusaricidin A (LI-F04a) analogs with the natural prod-
uct, it was determined that the natural product has fatty 
acid with (R)-absolute configuration. Two groups, Jen-
sen et al.53 and Park et al.,54 have recently reported 
identification and isolation of putative LI-F/fusaricidin 
synthetase gene, fusA, from P. polymyxa, opening the 
possibility for the development of biosynthetic ap-
proaches toward this family of naturally occurring cyc-
lic lipodepsipeptides and their analogs. 
 
SF-1902 A FAMILY 
SF-1902 A1−A5,
55,56 Figure 4, are cyclic lipodepsipep-
tides isolated in 1978 from four different strains of acti-
nomycetes. Their macrocyclic core is comprised of five 
amino acid residues and a -hydroxy--methyl carbox-
ylic acid. One compound named SF-1902 A1 has the 
same structure as globomycin57 24, whereas an addi-
tional five isolated compounds, A2, A3, A4a, A4b and A5 
(25−29) differ in the length of the fatty acid side chains 
and the amino acid residue in position 2 of the peptide 
macrocyclic core; SF-1902 A3 and SF-1902 A4b have 
Val2 instead of L-allo-isoleucine (L-aIle2), Figure 4. In 
this family of cyclic lipodepsipeptides, lactonization 
occurs between C-terminal Gly5 and the fatty acid’s 
hydroxyl group in position 3. Three amino acids are 
non-proteinogenic, N-Me-L-Leu, L-aThr and L-aIle. 
Globomycin’s crystal structure reported in 2000 by 
Kogen et al. revealed (R)-configuration in both fatty 
acid stereocenters.58 Natural product globomycin 24 
showed most potent activity against Gram-negative 
bacteria such as E. coli and K. pneumonia, with MICs of 
0.2 g/mL.57 Its mode of action involves inhibition of 
lipoprotein signal peptidase II (LspA), an integral mem-
brane protein which processes the acylated precursor 
form of lipoproteins into apolipoprotein and signal pep-
tide in bacteria.59,60 Specific inhibition of LspA leads to 
the accumulation of the lipoprotein precursor in the 
cytoplasmic membrane and consequently to bacterial 
cell death.61−63 Quite interestingly, Banaiee et al. dem-
onstrated that globomycin does not inhibit LspA in 
Mycobacterium tuberculosis and that the mode of action 
against this bacterial strain lacks any LspA-dependent 
activity.64 Globomycin is not cytotoxic to mouse L-cells 
in tissue culture with a minimal toxic concentration of 
250 g/mL. The LD50 value for intraperitoneal injection 
in mice was 115 mg/kg, but mice tolerated up to 400 
mg/kg when administered subcutaneously.57 
The total solution synthesis and structure-activity 
relationship (SAR) study reported by Kogen et al.58,65 
showed that the hydroxyl group in the Ser3 residue is 
essential for antibacterial activity, and the presence of a 
longer fatty acid side chain significantly increased the 
activity. A four-carbon atom increase in the fatty acid 
side chain length, from nine to thirteen carbons, led to a 
four- to eight-fold increase in activity against all Gram-
negative bacteria tested. Surprisingly, the globomycin 
synthetic analog containing the longest fatty acid side 
chain, 30, exhibited also activity against Gram-positive 
S. aureus strains with MICs ranging from 6.25 to 12.5 
g/ml, Table 3.65,66 On the other hand, derivatives with 
a modified macrocyclic core exhibited weak or no activ-
ity. For example, it was demonstrated that the L-aThr 
hydroxyl group is not important for activity, but its 
stereochemistry turned out to be essential. Modifica-
tions at the N-Me position caused conformational 
change in the peptide resulting in a loss of the bacteri-
 
Figure 4. SF-1902 family of cyclic lipodepsipeptides 24-29. 
Table 3. Antibacterial activity of globomycin analogs differ-
ing in the length of the fatty acid tail65 
MIC (g/mL) against S. aureus strains 
Globomycin 










 n = 3,   24 > 100 > 100 > 100 > 100 
 n = 5,   29 50 50 50 100 
 n = 7,   30 6.25 6.25 12.5 12.5 
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cidal activity.65,66 This group of natural products is a 
rare example of antimicrobial agents active against both 
Gram-positive and Gram-negative bacteria, representing 
particularly interesting lead structure(s) for the devel-
opment of novel broad-spectrum antibiotics. 
 
RAMOPLANINS/ENDURACIDINS 
In 1984 a research group from Gruppo Lepetit (Bio-
search Italia) isolated from a culture broth of Actinop-
lanes sp. ATCC 33076 an antibiotic complex named A-
16686, later renamed to ramoplanin, Figure 5. The iso-
lated antibiotic complex was a mixture of three structu-
rally similar compounds designated as A1−A3 31−33, 
out of which A2 32 represented the major component.67 
Initial studies, including chemical degradation, mass 
spectrometry and 2D NMR experiments, revealed the 
structural complexity of these antibiotics.68,69 Isolated 
compounds were identified to be cyclic lipoglycodepsi-
peptides containing 17 amino acids, including several 
nonproteinogenic amino acids such as L-hydroxyphe-
nylglycine (L-Hpg), D- and L-aThr, L-threo--hydro-
xyasparagine (L-tHyAsn), D-ornithine (D-Orn) and L-3-
chloro-4-hydroxyphenylglycine (L-Chp). The macro-
cycle is formed via lactone linkage between the L-Chp17 
carboxyl group and the L-tHyAsn2 -hydroxyl group. 
The latter one is also linked to Asn1 bearing an unusual 
unsaturated acyl chain on its N-terminus. In addition,  
L-Hpg11 residue carries a disaccharide moiety, -1,2-
dimannose, attached to its hydroxyl group. The amino 
acid sequence within the ramoplanin family of natural 
products is conserved; the only difference lies in the 
unsaturated acyl chain, Figure 5. The stereochemistry of 
ramoplanin’s acyl chain was initially assigned to be 
(2Z,4Z).68 However, this was subsequently reexamined 
and corrected to (2Z,4E).70,71 Ramoplanins are structu-
rally similar to ramoplanose 34, a trimannosylated ra-
moplanin isolated also from Actinoplanes sp.72 and to 
enduracidins. Enduracidins A 35 and B 36, Figure 6, 
were isolated in 1968 from Streptomyces fungicides 
 
Figure 5. Structures of ramoplanins A1-A3 31-33 and ramoplanose 34. 
 
Figure 6. Enduracidins A 35 and B 36. 
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B5477 culture broth.73,74 Enduracidins A and B differ 
only in the length of the lipid tail. Enduracidins are 17-
mer peptides forming a macrocyclic core composed of 
16-amino acids cyclized via lactone bridge between 
Thr2 and L-Hpg17 residues, Figure 6. The characteristic 
features of enduracidins are the amino acids D- and L-
enduracididine (D-, L-End), L-citrulline (L-Cit), and L-
3,5-dichloro-4-hydroxyphenylglycine (L-Dpg). Endura-
cidin and ramoplanin share a number of structural simi-
larities; however, enduracidins do not have a sugar 
moiety. These common structural features indicate a 
possible similarity in mode of action and a common 
active pharmacophore.75 The 3D NMR structure of 
ramoplanose revealed a double-stranded antiparallel -
sheet with seven intramolecular hydrogen bonds and 
two reverse turns.72 Almost identical structural characte-
ristics were found in ramoplanin A2. In 1996 Kurtz and 
Guba determined the 3D structure of ramoplanin A2 32 
in aqueous solution from multidimensional NMR expe-
riments. The structure is characterized by two antiparal-
lel -sheets connected with six intramolecular hydrogen 
bonds and one reverse -turn.70 Quite interestingly, 
Walker et al.76 showed that ramoplanin A2 in methanol 
forms a symmetric dimer at the interface of amino acid 
residues 10−14, and is stabilized with four intermolecu-
lar hydrogen bonds. In 2009 McCafferty et al. reported 
the first X-ray structure of ramoplanin A2, showing that 
ramoplanin A2 in the crystal forms an amphiphatic 
dimer with C2 symmetry. This mutual orientation of 
monomers allows formation of a four-stranded antipa-
rallel -sheet, whose interface consists of amino acid 
residues 9−15 and six intermolecular hydrogen bonds.77 
The fact that ramoplanin A2 forms dimers in a hydro-
phobic solvent that mimics the environment at the bac-
terial cell surface and in the crystal may indicate the 
manner in which this antibiotic interacts with its bac-
terial target.  
As expected, due to partial amino acid sequence compa-
rability, the overall backbone structure of enduracidin 
and ramoplanin share a high degree of similarity.78 
Enduracidin’s structure is characterized by two antipa-
rallel -sheets that include residues 5−7 and 10−12 
connected by a turn composed of the residues 8 and 9. 
Three hydrogen-bonding interactions stabilizing this -
hairpin arrangement are between residues D-aThr5 and 
D-Ser12, D-Hpg7 and D-End10, and D-Hpg7 and L-Cit9.78 
Ramoplanins A1−A3 31−33 possess identical an-
tibiotic activities, and are active against Gram-positive 
bacteria, including resistant strains such as VRE and 
MRSA with MICs below 1 g/mL.79−83 They have a 
similar spectrum of antibacterial activities as vancomy-
cin, but they are 4−8 times more potent.84 In addition, 
ramoplanin A2 32 exhibits bactericidal activity at con-
centrations close to MICs for most Gram-positive bacte-
ria, and at concentrations twice the MIC value against 
VRE, while vancomycin only displays bacteriostatic 
activity at its MICs.82,85 Ramoplanins A1−A3 exhibit no 
activity against Gram-negative bacteria.84,86 Soon after-
ward, three other ramoplanin analogs were isolated from 
the culture broth of the producing microorganism and 
designated as A1’−A3’, differing from A1−A3 in the -
glycosidic moiety. Ramoplanins A1’−A3’ contain only 
a monosaccharide unit.87 Interestingly, A2’ showed 
better activity against certain bacterial strains than A2; 
otherwise, their antimicrobial activities are similar.87 
Enduracidins exhibited a similar spectrum of antibac-
terial activities to ramoplanins, whereas no data for 
ramoplanose antibacterial activity was reported.  
SAR studies were performed by several groups in 
order to determine important structural characteristics 
modulating antibacterial activity. Ciabatti et al. prepared 
deglycosylated ramoplanin analogs, and analogs con-
taining saturated N-terminal fatty acid chains.68 These 
modifications had no significant effect on ramoplanin’s 
antibacterial activity. McCafferty et al. had also re-
ported synthesis of several semi-synthetic ramoplanin 
analogs with modifications on the D-Orn4 and D-Orn10 
side chains.75 Guanidylation or reductive amination of 
the Orn residues had minimal to moderate effects on 
ramoplanin’s antimicrobial activity. In contrast, loss of 
the cationic charge by Orn acetylation, and hydrolysis 
of the lactone linkage severely diminished or fully de-
leted depsipeptide’s activity.75,88,89 Total solution-phase 
syntheses of ramoplanin A2, ramoplanose aglycon, and 
ramoplanin A1−A3 aglycons, were accomplished by 
Boger et al.71,88−90 The retrosynthetic analysis was de-
signed around ramoplanin A2 3D structure in solution. 
Based on this analysis, three linear peptide precursors 
(heptapeptide composed of residues 3−9, pentadepsi-
peptide composed of residues 1,2 and 15−17, and pen-
tapeptide composed of residues 10−14) were prepared, 
sequentially coupled and cyclized to yield the ramopla-
nin aglycon macrocyclic core. The coupling sites were 
chosen to maximize the efficacy of the synthesis, pre-
vent potential racemization that may occur during the 
final macrocyclization step, and to promote formation of 
a -sheet secondary structure of the linear 17-amino-
acid precursor that would facilitate the final macrocycli-
zation step. Ramoplanin A1 and A3 aglycons were 
prepared by acylation introduction of the lipid side-
chains onto the synthetic ramoplanin macrocyclic 
core.91 In order to provide a more chemically stable 
alternative to natural ramoplanin A2, two amide aglycon 
analogs have been synthesized where L-tHyAsn2 has 
been replaced by L-2,3-diaminopropionic acid (L-Dap) 
or L-2,4-diaminobutyric acid (L-Dab).92 The L-Dap-
analog maintained the same activity as ramoplanin A2, 
whereas the ring extension by one methylene group, L-
Dab-analog, led to a loss of antibiotic activity. Recently, 
Boger et al. reported an alanine-scan on ramoplanin’s  
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L-Dap-analogue providing insight into the potential role 
and importance of each amino acid residue for its anti-
bacterial activity.93 In contrast, there are no reports on 
the total synthesis of enduracidins. However, biosynthe-
sis of enduracidin A 36 analogs with altered halogena-
tion patterns has been reported in 2010, and initial in 
vitro antibacterial evaluation showed that these analogs 
retained activity against S. aureus.94  
In 1990 Somner and Reynolds showed that ramop-
lanin blocks bacterial cell wall biosynthesis at the step 
catalyzed by membrane-associated glycosyltrensferase 
MurG.95 They proposed a mechanism of action that 
involves ramoplanin binding to MurG substrate Lipid I 
and inhibition of Lipid II formation. Eight years later, 
Brötz, et al. showed that ramoplanin, as well as some 
lantibiotics, interacted with Lipid II, and raised a ques-
tion of a possible second mode of action for ramopla-
nin.96 Recently Walker et al. demonstrated that ramop-
lanin has higher affinity for Lipid II, and proposed the 
transglycosylation step as the primary target. Inhibition 
kinetic experiments revealed that ramoplanin binds 
Lipid II with a stoichiometry of 2:1.97 Interestingly, 
fibril formation of Lipid II analogs was observed upon 
titration with ramoplanin.75,98 Walker’s group also found 
that ramoplanin inhibits MurG by the mechanism that 
does not include binding to Lipid I, but rather via direct 
interaction with the enzyme.99 However, since Lipid I 
and MurG are intracellular, and therefore not accessible 
to ramoplanin,98,100 and considering ramoplanin’s higher 
affinity toward Lipid II, it is not clear whether inhibition 
of MurG is of physiological relevance. Enduracidin has 
an almost identical mode of action as ramoplanin.97 The 
main difference is in the MurG inhibition. Ramoplanin 
displayed noncompetitive inhibition of MurG, whereas 
enduracidin produced an inhibition curve consistent 
with substrate binding.97 Ramoplanin is currently in 
Phase II trial for the treatment of Clostridium difficile 
associated diseases (CDAD), and in Phase III develop-
ment for the prevention of vancomycin-resistant entero-
cocci bloodstream infections. Enduracidin has been 
shown to be effective in humans for treating urinary 
tract and skin infections caused by methicillin-resistant 
S. aureus.101 No toxicity or side effects for enduracidin 
in these trials were reported.  
 
DAPTOMYCIN 
In the early 1980s, a group at Lilly Research Laborato-
ries isolated a series of novel antibiotics designated as 
A21978A, B, C, D and E from Streptomyces roseospo-
rus NRRL 11379 culture broth, Figure 7.102 The major 
component, A21978C, was highly active against Gram-
positive bacteria.103 RP HPLC analysis of A21978C 
showed the presence of six compounds (C0−C5), out of 
which three compounds were most abundant, 
A21978C1−C3 38−40. Structural analysis revealed all 
compounds to be cyclic lipodepsipeptides comprised of 
13 amino acid residues, 5 of which were unusual amino 
acids, including L-ornithine (L-Orn), L-threo-3-
methylglutamic acid (L-3-MeGlu), L-kynurenine (L-
Kyn) and two D-amino acid residues. Initially, Asn2 
configuration was assigned as L, and recently this assig-
nation was corrected to a D-configuration.104 Ten amino 
acids form the depsipeptide macrocyclic core with a 
lactone linkage between the L-Kyn13 carboxyl group and 
the Thr4 hydroxyl group. The remaining tripeptide, 
Asp3-Asn2-Trp1, is attached to the Thr4 carboxyl group. 
The amino acid sequence is conserved in all six C0−C5 
daptomycins. The structural differences lie in the fatty 
acid chain attached to the Trp1 amino group. In the 
compounds C1−C3 38−40, the fatty acid chain was 
found to be anteiso-undecanoyl, iso-dodecanoyl and 
anteiso-tridecanoyl. A minor compound of the complex 
C0, was found to have a mixture of both linear and 
 
Figure 7. Structures of daptomycin 37 and A21978C1−C3 38−40. 
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branched decanoyl, while C4 and C5 both contain dode-
canoyl fatty acids.105 Daptomycin 37, a member of the 
A21978C complex, contains a straight C10 lipid side-
chain, Figure 7.  
Comparison of A21978C1 activity with those of 
vancomycin, teichomycin and several -lactam antibio-
tics, showed that A21978C1 was at least as active as 
vancomycin against all streptococci and staphylococci 
tested, including MRSA and penicillin-resistant pneu-
mococci.106 It was also found to be bactericidal against 
enterococci at concentrations close to MICs (2 g/mL). 
When combined with gentamycin, a bactericidal synerg-
ism was observed by time-kill methods.106 A21978C1 
did not interact with penicillin-binding proteins of bac-
terial cell membranes nor did it interfere with the DNA, 
RNA or protein synthesis. However, it inhibited pepti-
doglycan biosynthesis of both S. faecalis and S. aureus. 
Even more interesting was the finding that activity of 
this family of naturally occurring antibiotics strongly 
depends on the concentration of Ca2+ in the culture 
medium, whereas no increase in activity was observed if 
medium is supplemented with Mg2+, Zn2+ or Ba2+.106 
A21978C’s maximum antibacterial potency is reached 
at the Ca2+ concentration of 50 mg/L (1.25 mM); the 
concentration of ionized calcium normally found in 
human serum.107 It has also been shown that these anti-
biotics cause potassium release from S. aureus, suggest-
ing that their bacterial target is membrane and/or cell 
wall.108,109 This behavior is similar to one of calcium-
dependent antibiotic (CDA) which forms ion-
conducting channels in planar phospholipid mem-
branes.110 The activity of A21978C antibiotics was 
proposed to be very complex, depending on incorpora-
tion of the antibiotic into bacterial membrane. Studies 
performed by Lakey et al. and recently by Jung et al. on 
daptomycins’ interaction with phospholipid vesicles and 
Ca2+, suggested that charge neutralization through Ca2+ 
complexation facilitates penetration of the peptide into 
the membrane.111,112 It was found that the extent of pe-
netration into the lipid bilayer is inversely proportional 
to the side chain length, indicating that Ca2+ dependent 
interaction is a specific interaction involving the polar 
head groups of the phospholipids and the daptomycins, 
with the role of the lipidic side chain being most impor-
tant for the initial antibiotic attachment to the mem-
brane. However, the length of the side chain was shown 
to influence the peptide’s toxicity. Peptides bearing 
longer side-chain fatty acids exhibited higher toxicity. 
The optimal balance between toxicity and antimicrobial 
activity was obtained with daptomycin, an A21978C 
derivative containing a decanoyl chain.113,114 In 1988 
Huber et al. reported large quantity production of de-
sired daptomycin by supplying decanoic acid during S. 
roseosporus fermentation.115 The lack of suitable solu-
tion or solid-phase synthetic approaches toward dapto-
mycin and its analogs makes chemoenzymatic methods 
important alternatives to generate and scale up dapto-
mycin derivatives for antibacterial screening and drug 
development. Chemoenzymatic methods usually com-
bine standard solid-phase peptide synthesis (SPPS) with 
enzymatic peptide cyclization mediated through excised 
thioesterase (TE) domains from NRPSs.116−118 Antibac-
terial activity studies of chemoenzymatically synthe-
sized daptomycin derivatives revealed that four amino 
acids, Asp7, Asp9, and L-3-MeGlu12 and L-Kyn13, are 
important for the peptide’s antibacterial potency. Fur-
thermore, derivatives containing different macrocyclic 
core size were prepared by shifting the Thr4 residue to 
position 3, 5 or 6 in the linear precursor generating 8, 9 
and 11-membered rings.118 Genetic engineering of the 
NRPS in the daptomycin biosynthesis was further ex-
ploited for combinatorial biosynthesis of novel antibio-
tics. Baltz et al. combined NRPS module exchanges, 
NRPS subunit exchanges, inactivation of the tailoring 
enzyme glutamic acid 3-methyltransferase, and natural 
variation of the lipid tail to generate a library of dapto-
mycin analogs.104,119,120 These bioengineered daptomy-
cin analogs include modifications at the L-Kyn13 posi-
tion, and modifications of the daptomycin macrocyclic 
core at residues that are not conserved among structural-
ly related lipopeptides. Some of these analogs were as 
active as daptomycin, demonstrating that the combina-
torial biosynthesis is an effective tool to generate dap-
tomycin analogs with significant structural diversity for 
further clinical evaluation.  
A semisynthetic method was also successfully ap-
plied to modify the daptomycin amino acid core. In an 
attempt to enhance the potency of daptomycin, Parr et 
al. synthesized a series of N-acylated L-Orn6 analogs 
using activated esters, anhydrides, and guanidinylating 
reagents.121 Based on the MIC data, it was shown that 
the Orn6 amino group is not essential for daptomycin’s 
antibacterial activity. Some analogs maintaining a free 
amine in the Orn region showed similar or slightly bet-
ter antibacterial activity, and significantly different 
pharmacokinetic profiles than daptomycin. 
Although it is well established that daptomycin 
exerts its mode of action on the bacterial cell membrane 
in Gram-positive bacteria, its precise mode of action has 
not been completely clarified. Initially, Allen et al. have 
shown that daptomycin has a disruptive effect on mem-
brane permeability as demonstrated by the loss of intra-
cellular potassium upon bacteria exposure to the pep-
tide. The fact that this antibiotic inhibited incorporation 
of [14C] alanine and [14C]DAP into the peptidoglycan of 
S. aureus and Bacillus megaterium, and the lack of any 
significant inhibition of protein, RNA, DNA or lipid 
biosynthesis indicated that the membrane is not likely a 
lethal target for this antibiotic. Instead, they suggested 
that daptomycin inhibits formation of peptidoglycan 
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precursor, UDP-MurNAc-pentapeptide.122 Silverman et 
al. proposed a multistep mode of action for daptomy-
cin.109 According to the proposed mechanism, in the 
first step, daptomycin binds weakly to the cytoplasmic 
membrane and complex Ca2+. This causes conforma-
tional change, and leads to daptomycin’s insertion into 
the plasma membrane and its subsequent oligomeriza-
tion. In the second step, daptomycin oligomers form a 
channel through which intracellular potassium ion is 
lost, leading to membrane depolarization and bacterial 
cell death. Recently, a more complex mode of action 
was proposed for daptomycin. In 2004 Hancock et al. 
suggested that the bactericidal action of daptomycin is 
not exclusively a result of the membrane depolarization, 
but rather daptomycin’s interaction with several bacteri-
al components such as cell wall, various enzymes, RNA 
and DNA.112 Chopra et al. in 2008 re-examined the 
daptomycin mode of action proposed by Silverman et 
al. by performing more detailed experiments on kinetics 
of membrane depolarization and loss of K+, Mg2+, and 
ATP.123 Obtained experimental data showed that dap-
tomycin-induced efflux of Mg2+, and ATP occurs in 
conjunction with K+ leakage. Based on these findings, 
Chopra et al. proposed that the bactericidal activity of 
daptomycin is not simply a consequence of K+ efflux 
and probably involves more general disruption of the 
membrane.  
Although Eli Lilly and Co. began development of 
daptomycin in 1985, they later abandoned further pur-
suit due to Phase II clinical trial results which showed 
the occurrence of potential drug-induced myopathic 
events.124 In 1997 Cubist Pharmaceuticals Inc. licensed 
daptomycin and re-instigated clinical development of 
the drug. To determine the dosing regimen with poten-
tially lower muscle toxicity two studies were conducted 
with dogs. Repeated intravenous administration every 
24 h versus every 8 h for 20 days indicated that once-
daily administration appeared to have minimized poten-
tial for daptomycin-induced skeletal-muscle effects.125 
Further clinical trials were conducted using a single 
daily dose of the antibiotic. Daptomycin was approved 
in the United States in 2003 for treatment of compli-
cated skin and skin structure infections associated with 
methicillin-susceptible S. aureus (MSSA), MRSA, S. 
pyogenes, Streptococcus agalactiae, Streptococcus 
dysgalactiae subsp. equisimilis and E. faecalis (vanco-
mycin-susceptible only) and in 2006 for treatment of 
bacteraemia and right-sided endocarditis caused by 
MSSA and MRSA.126,127 Also, it was approved in Eu-
rope in 2006 for treatment of complicated skin and soft 
tissue infections. Daptomycin is marketed under the 
trade name Cubicin. 
Although daptomycin exhibits strong activity 
against variety of Gram-positive bacteria including S. 
pneumoniae, the experimental and clinical data for mice 
and humans showed that daptomycin lacks efficacy 
against Gram-positive bacterial infections of the lung.128 
In phase III clinical trial for the treatment of patients 
with community-acquired pneumonia (CAP) daptomy-
cin (applied at a dose of 4 mg/kg) failed to achieve 
superiority over ceftriaxone, a drug of choice for the 
treatment of CAP. Reported efficacies for daptomycin 
and ceftriaxone are 79 % and 87 %, respectively.128 
Daptomycin's poor efficacy against CAP may be attri-
buted to its interaction with pulmonary surfactant com-
ponents.129 Recent attempts to generate more potent 
daptomycin derivatives in the presence of bovine sur-
factant utilize combinatorial biosynthesis approach.130 
A5415 is a complex of eight cyclic lipodepsipep-
tide antibiotics produced by Streptomyces fradiae and 
structurally similar to daptomycin, Figure 8.131−134 These 
antibiotics exhibited potent activity against S. aureus 
and S. pyogenes infections in mice. However, acute 
mouse toxicities hampered their further development as 
a novel drug.135 Some of these antibiotics were shown to 
be much less inhibited by bovine surfactant than dapto-
mycin, providing therefore a lead structure for modifica-
tions to explore structure-activity relationship (SAR) 
around A5415. Very recently, Baltz et al. reported prep-
aration of several A5415 analogs by modifying the 
A5415 NRPS using segments of the daptomycin NRPS 
genes.136−138 Three mutants defective in IptJ, IptK or 
IptL genes encoding the enzymes involved in biosyn-
thesis of hydroxy-Asn3 and methoxy-Asp9 were generat-
ed. These deletions were combined with deletion of the 
IptI gene involved in biosynthesis of 3-methyl-Glu12 and 
with the plasmid containing combination of Ipt genes to 
produce a series of novel A5415/daptomycin analogs. 
For all the compounds, removal of the methoxy group 
Figure 8. Representative member of the A54145 family, 
A54145A. 
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from Asp9 and the hydroxy group from Asn3 yielded 
compound A5415(Asn3Asp9) with comparable antibac-
terial activity to the parent A5415 or daptomycin, and 
without loss in activity in the presence of bovine surfac-
tant.137 The structure of A5415(Asn3Asp9) predicted 
from the genetic changes and bioinformatics studies was 
confirmed by chemical transformations, amino acid 
quantitation by enantiomer labeling, LC-MS/MS and 
2D NMR techniques.138 This approach creates new 
possibilities for daptomycin SAR, and discovery of new 
and more potent antibiotics of this class. 
 
OTHER LIPODEPSIPEPTIDES PRODUCED BY 
Pseudomonas spp. 
Plant pathogenic bacteria Pseudomonas spp. produce a 
variety of biologically active compounds, including 
nonribosomally synthesized cyclic lipodepsipeptide 
phytotoxins. Different ecotypes of Pseudomonas syrin-
gae pv. syringae produce structurally closely related 
lipodepsipeptides such as syringomycins 41, syringosta-
tins 42 and syringotoxin 43, Figure 9.139−146 Another 
structurally similar compound, pseudomycin 44, was 
isolated from P. syringae MSU 16H, a bacterium pro-
posed for the biocontrol of the causal agent of the highly 
destructive Dutch elm disease, Figure 9.147 The structur-
al similarities among these lipodepsipeptides initiated 
efforts to investigate their biosynthetic pathways and 
their biological activities. All these lipopeptide phyto-
toxins contain a polar cyclic nonapeptide head and an 
unbranched 3-hydroxy fatty acid side chain of different 
lengths, Figure 9. The four lipodepsipeptides have a 
common C-terminal sequence consisting of Z-
dehydrobutyric acid (Z-Dhb), L-tHyAsp, and L--
chlorothreonine (L-Cl-Thr). The greatest differences are 
in the amino acid sequences between positions 2 and 6. 
Besides proteinogenic amino acids, peptide sequence in 
these positions also contains residues such as D-Ser, L-
aThr, D- and L-2,4-diaminobutyric acid (D- or L-Dab), 
and D-homoserine (D-Hse). A macrocyclic ring is 
formed by a lactone linkage between the Ser1 side chain 
hydroxyl group and the Cl-Thr9 carboxyl group. Similar 
to the previous cases, these lipodepsipeptide phytotox-
ins are synthesized nonribosomally by 470 kDa or larger 
NRPSs.148,149 To our knowledge, there are no reports on 
their total synthesis or of the preparation of synthetic or 
bioengineered analogs. All lipodepsipeptides show 
similar phytotoxicity.139,147,150 Lipid bilayer studies 
showed that the probable mode of action involves inser-
tion onto the target plant plasma membrane with forma-
tion of ion channels, causing ion flux and cell death.151 
Syringopeptins are another interesting group of li-
podepsipeptides produced by P. syringae pv. 
syringae.152 They share many of the structural features 
of previously discovered lipodepsinonapeptides, Figure 
10.153 Syringopeptins are composed of 22 or 25 amino 
acid residues. Eight residues form the macrocyclic dep-
sipeptide core to which a peptidyl chain containing 3-
hydroxy fatty acid is attached. Interestingly, the amino 
acid sequence varies with syringopeptins producing P. 
syringae pv. syringae strains isolated from different 
sources.152−155 Like other lipodepsinonapeptides from 
this group, they contain several nonproteinogenic amino 
acids, including L-Dab, L-Dhb, L-aThr, in addition to D- 
and L-amino acids. In fact, most of the residues in the 
peptidyl chain are of D-configuration.153 The fatty acid 
tail can be either decanoic or dodecanoic acid.152 Hut-
chison and Gross suggested that syringopeptin and re-
lated lipodepsipeptide syringomycin aggregation is 
required for pore forming in lipid bilayers.150 In addition 
 
Figure 9. Representative lipodepsinonapeptides from Pseudomonas sp. 
Figure 10. Representative syringopeptins SP 22-A 45 and SP 25-A 46. 
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to their phytotoxic activity, syringopeptins exhibit noti-
ceable antibiotic properties as well.156−158 Syringopep-
tins are active against Gram-positive bacteria such as B. 
megaterium, S. aureus, S. pyogenes, and Mycobacte-
rium smegmatis with 0.98−7.8 µg/mL MIC range.156−158 
These lipodepsipeptides are not active against Gram-
negative bacteria. The most probable antibacterial mode 
of action involves pore formation in the host membrane 
leading to cytolysis.139,150,151 Takemoto et al. suggested 
that the cell wall anionic teichoic acids modulate syrin-
gopeptin action and promote selective activity against 
Gram-positive bacteria such as Bacillus subtilis. How-
ever, the molecular basis for their antibacterial activities 
is not yet completely elucidated. Besides antibacterial 
activity, all lipodepsipeptides inhibit the growth of fun-
gi. The antifungal activity also involves the lipid bilayer 
membrane, but the activities are affected by membrane 
composition, especially by sphingolipids and ste-
rols.156,159−162 Lipodepsipeptide phytotoxins have also 
been proven to induce human and rabbit red blood cell 
lysis.150,156,159,163−165 These amphipathic compounds 
insert themselves into the membrane bilayer and form 
pores, causing efflux of H+, K+ and Ca2+ and cell 
death.165−170 Taking into consideration the potent anti-
fungal activity of these lipodepsipeptides and due to 
high human and animal red blood cell toxicity, their 
potential future development may be rather directed 
toward agricultural applications. 
 
SUMMARY 
Occurrence of multidrug-resistant pathogens and urgent 
demands for new and more potent antimicrobials place 
this class of natural products in the center of attention 
for development of new antibacterial agents. Some of 
those compounds, such as cyclic lipodepsipeptide dap-
tomycin 37, Figure 7, (Cubicin, Cubist Pharmaceuticals, 
Inc.) are already approved in the USA, European Union 
and Canada for the treatment of bloodstream and com-
plicated skin infections caused by multidrug-resistant 
bacterial strains. Ramoplanin A2 32 (Oscient Pharma-
ceuticals Corporation) is another good example of cyc-
lic depsipeptide potential in the development of new 
antibiotics, Figure 5. Ramoplanin is currently in a Phase 
II trial for the treatment of C. difficile-associated diarr-
hea (CDAD) and in Phase III development for the pre-
vention of vancomycin-resistant enterococci blood-
stream infections. Despite the progress in development 
of new antibacterial agents, it is inevitable that resistant 
strains of bacteria will emerge in response to wide-
spread use of a particular antibiotic and limit its useful-
ness. Therefore, development of new antibiotics remains 
our most efficient way to combat multi-drug bacterial 
resistance. 
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